Ensuring Drug Quality with the Favipiravir Quantification Method

Researchers have recently introduced a highly sensitive Favipiravir quantification method to enhance the quality control of antiviral medications. This drug serves as a critical therapeutic agent for managing RNA viral infections, particularly during the COVID-19 pandemic and seasonal influenza outbreaks. Consequently, maintaining the stability and purity of pharmaceutical formulations remains a top priority for manufacturers. This new analytical approach specifically addresses the need for a rapid and reliable way to measure drug concentration while identifying potential impurities.

Innovative Aqueous-Based Spectrofluorimetric Analysis

The established technique leverages the intrinsic fluorescence of the drug molecule. Specifically, the method utilizes first-order derivative processing to achieve a linear response within a remarkably low concentration range of 5 to 80 ng/mL. Furthermore, the researchers optimized key methodological parameters to improve sensitivity. This effort resulted in a detection limit of 1.6 ng/mL. Most importantly, the process occurs entirely in distilled water. Therefore, analysts can bypass hazardous organic solvents or complex buffers, which significantly reduces the environmental footprint of the laboratory work.

Stability-Indicating Capabilities and Green Metrics

A primary advantage of this Favipiravir quantification method is its ability to distinguish the active drug from its acid-induced degradation product (ADP). Scientists characterized the ADP using infrared spectroscopy and mass spectrometry to ensure the method's specificity. Moreover, the team evaluated the environmental impact using GAPI, AGREE, and RGB12 metrics. These assessments confirmed that the approach aligns with green chemistry principles. Thus, it offers a sustainable alternative to traditional chromatographic methods that often rely on toxic chemicals.

Practical Application in Pharmaceutical Analysis

The method proved effective for both pure drug substances and finished pharmaceutical dosage forms. Because it is rapid and cost-effective, it provides an excellent tool for routine quality control in pharmaceutical labs. In contrast to earlier fluorimetric methods, this aqueous-based operation provides superior analytical performance and improved safety for laboratory personnel. Ultimately, this development supports the global effort to provide high-quality antiviral treatments through efficient and eco-friendly technology.

Frequently Asked Questions

Why is an aqueous-based method preferred for drug analysis?

Aqueous-based methods eliminate the need for organic solvents, which are often toxic and expensive. This makes the laboratory process safer for the environment and more cost-effective for the manufacturer.

How does the method handle drug degradation?

The technique uses first-order derivative spectrofluorimetry. This mathematical processing allows the system to accurately measure the active drug even when degradation products are present in the sample.

Is this method suitable for routine laboratory use?

Yes, its high sensitivity, speed, and lack of complex reagents make it ideal for routine quality control and stability testing in the pharmaceutical industry.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a recommendation for any specific pharmaceutical product. Always consult with a qualified healthcare professional regarding drug formulations and therapeutic choices. Refer to the latest local and national guidelines for clinical practice.

References

1. El-Fattah MHA et al. A sensitive, aqueous-based spectrofluorimetric approach for the determination of favipiravir in presence of its acid-induced degradation product. BMC Chem. 2026 Feb 10. doi: 10.1186/s13065-026-01724-1. PMID: 41668202.

2. Soujanya V, Nalanda RB. Stability-Indicating Reverse Phase-HPLC Method Development and Method Validation for Quantitative Determination of Degradation Products in Favipiravir API and Drug Product. Int J Trop Dis Health. 2024;45(6):10-25.

3. Imam MS et al. Adjusted green spectrophotometric determination of favipiravir and remdesivir in pharmaceutical form and spiked human plasma sample using different chemometric supported models. BMC Chem. 2023;17(1):74.